M1A.4591 Other secondary chronic gout, unspecified hip, with tophus (tophi)

Name of the Condition

• Other Secondary Chronic Gout, Unspecified Hip, with Tophus (tophi)

Summary

Other secondary chronic gout, unspecified hip, with tophus (tophi) is a form of arthritis affecting the hip joint, resulting from elevated uric acid levels due to an identifiable underlying condition or cause. It leads to recurrent joint inflammation and potential tissue damage, with symptoms that may persist over time. Advanced stages involve the formation of tophi (urate crystal deposits) in the hip area.

Causes

Other secondary chronic gout, unspecified hip, with tophus arises from an underlying condition that disrupts uric acid metabolism, causing accumulation in the blood. This can stem from overproduction of uric acid or reduced renal clearance due to factors like chronic kidney disease, certain medications, or hematologic disorders. Over time, urate crystals deposit in the hip joint and surrounding tissues, triggering inflammation and tophi formation.

Risk Factors

• Underlying conditions that affect uric acid metabolism (e.g., certain hematologic disorders, enzyme deficiencies)
• Medications that increase uric acid levels (e.g., some diuretics, chemotherapy agents)
• Chronic kidney disease or renal impairment
• History of gout or hyperuricemia
• Exposure to substances that disrupt uric acid excretion

Symptoms

• Recurrent episodes of intense hip pain, often with swelling and redness
• Persistent warmth and tenderness in the hip joint
• Stiffness and limited range of motion
• Visible or palpable tophi (urate crystal deposits) in the hip area
• Chronic joint damage over time

Diagnosis

Diagnosis involves a combination of clinical evaluation, patient history, and laboratory tests. Joint fluid analysis may confirm urate crystals, while imaging (e.g., X-rays, ultrasound) can detect tophi or joint damage. Blood tests assess uric acid levels and rule out underlying conditions contributing to secondary gout.

Treatment Options

Treatment focuses on managing uric acid levels, reducing inflammation, and addressing underlying causes. Medications may include urate-lowering agents, anti-inflammatories, or colchicine. Lifestyle modifications, such as dietary changes and hydration, support long-term management. Tophi may require specialized care if symptomatic.

Prognosis and Follow-Up

Prognosis depends on timely treatment and management of underlying conditions. With proper care, symptoms can be controlled, and tophi may reduce in size. Regular follow-up is essential to monitor uric acid levels, adjust therapies, and prevent complications like joint damage.

Complications

• Chronic joint damage or deformity
• Persistent pain and functional impairment
• Infection of tophi
• Kidney stones or renal impairment (if uric acid levels remain uncontrolled)

Lifestyle & Prevention

• Maintain a balanced diet low in purines (e.g., limit red meat, seafood)
• Stay hydrated to support uric acid excretion
• Avoid alcohol and sugary beverages
• Manage weight and exercise regularly
• Follow prescribed medication regimens consistently

When to Seek Professional Help

Seek care if experiencing severe or persistent hip pain, swelling, or stiffness. Prompt evaluation is needed if tophi appear, symptoms worsen, or there are signs of infection (e.g., fever, increased redness). Early intervention helps prevent long-term damage.

Tips for Medical Coders

Document the presence of tophi and specify the hip as the affected site. Ensure underlying causes of secondary gout are clearly recorded, as these influence code assignment. Verify that the hip is documented as "unspecified" when no laterality is indicated.